Quantcast

Latest Cadence Pharmaceuticals Inc. Stories

2010-02-11 06:30:00

SAN DIEGO, Feb. 11 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for intravenous (IV) acetaminophen. In the Complete Response letter, the FDA only indicated that deficiencies were observed during the FDA's facility inspection of Cadence's third party manufacturer, which was completed on February 5, 2010. The FDA did not cite...

2009-11-13 06:30:00

SAN DIEGO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months. The extended PDUFA goal date is February 12, 2010. "We remain confident in our NDA submission and will continue to work closely with the FDA toward the...

2009-11-05 15:01:00

SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2009. Based upon the Priority Review designation granted by the FDA for Cadence's New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), the...

2009-10-29 15:15:00

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2009 financial results after the market closes on Thursday, November 5, 2009. Cadence management will host a conference call and live webcast to discuss the financial...

2009-10-28 17:00:00

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Wednesday, November 4, 2009 at 2:45pm Eastern Time (11:45am Pacific Time) during the Oppenheimer 20th Annual Healthcare...

2009-10-20 16:00:00

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 27, 2009 at 10:30am Pacific Time (1:30pm Eastern Time) during the BIOCOM Investor Conference at the Hyatt...

2009-09-30 07:00:00

SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it will host a live webcast of its Analyst Day on Wednesday, October 7, 2009 at 11:30 a.m. Eastern Time. Cadence's senior management team, led by Ted Schroeder, President and Chief Executive Officer, will provide an...

2009-09-29 17:30:00

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 6, 2009 at 2:00pm Eastern Time (11:00am Pacific Time) during the JMP Securities Healthcare Focus...

2009-09-09 16:00:00

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will be presenting at the following investment conferences: Senior Vice President and Chief Commercial Officer Scott Byrd will present on Wednesday, September 16, 2009 at 10:30am Eastern Time (7:30am Pacific...

2009-08-05 15:01:00

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2009. During the second quarter of 2009, Cadence submitted its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related